1 / 34

BOOP

BOOP. BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA ( a review ) . BUHMC. THE BROOKDALE UNIVERSITY HOSPITAL & MEDICAL CENTER BROOKLYN, NEW YORK, NY, 11212 SIVAKUMAR PADMANABHAN, MD FELLOW, PULMONARY MEDICINE. BOOP--INTRODUCTION.

clemens
Download Presentation

BOOP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BOOP BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA ( a review )

  2. BUHMC THE BROOKDALE UNIVERSITY HOSPITAL & MEDICAL CENTERBROOKLYN, NEW YORK, NY, 11212 SIVAKUMAR PADMANABHAN, MD FELLOW, PULMONARY MEDICINE

  3. BOOP--INTRODUCTION • Bronchiolitis Obliterans - refers to a generic term of non-specific inflammatory reaction of small airways in response to exogenous/endogenous stimuli • Comprises two types - based on histopathology • Clinical features mimic pneumonia without response to antibacterial therapy

  4. BOOP - INTRODUCTION • Once BOOP is documented - look for a precipitating factor • Rx: Steroids/Immunosuppressive agents • Prognosis: Excellent for idiopathic BOOP

  5. Constrictive or Obliterative Bronchiolitis- Concentric Narrowing of Bronchioles with fibrous tissue --> airflow limitation Proliferative Bronchiolitis- Exuberant Granulation tissue and intraluminal plugs of connective tissue(Masson body) in respiratory bronchiole, alveolar duct and alveoli OB vs BOOP

  6. BOOP- EPIDEMIOLOGY • First described in 1901 by Lange • 1985-- More cases reported by Epler et al • Age incidence: 4th- 7th decades • No gender predominance seen • Incidence: 6-7 per 100,000 admissions • Smoking is not a risk factor

  7. SECONDARY BOOP IDIOPATHIC BOOP BOOP- Classification

  8. SECONDARY BOOP • Connective tissue disorders - SLE, RA, Polymyositis - Dermatomyositis, Sjogren’s syndrome, MCTD, Ulcerative Colitis, Vasculitis • Inhaled/Systemic Toxins - gases, nicotine, cocaine, CO, nitrogen, chlorine • Drugs - Penicillamine, Amiodarone, Gold, Bleomycin, Mitomycin-c, Methotrexate, Sulfasalazine

  9. SECONDARY BOOP • Interferon Rx for Hepatitis C - reported Chest 1994 Aug; 106 (2):612-3 Ogata k, Koga T, Yagawa K, Japan

  10. SECONDARY BOOP • Infections: • Mycoplasma, HIV, HSV, CMV, Rubeola, Klebsiella, Hemophilus, Legionella, Grp B- Strep, Cryptococcus, Nocardia, PCP • Pediatric • RSV, Parainfluenza, Adenovirus, Mycoplasma

  11. SECONDARY BOOP • Obstructive Pneumonitis • Hypersensitivity Pneumonitis • Aspiration Pneumonitis • Chronic Eosinophilic Pneumonia • Diffuse Alveolar Damage • Myelodysplastic Syndrome • Hematological malignancy

  12. SECONDARY BOOP • Allograft transplant • Heart, Lung, Bone Marrow • 5-15% in those with GVHD • 1% of Allogenic transplant recepients without GVHD or in Autologous transplant recepients • IPF, ARDS

  13. BOOP - CLINICAL FEATURES • SUBACUTE illness: • non-productive cough • exertional dyspnea - few weeks • Constitutional symptoms: • fever, malaise, weight loss • one- third have a preceding upper respiratory tract infection • MIMICS Community Acquired Pneumonia

  14. BOOP- CLINICAL FEATURES • Physical exam : • Tachypnea, Crackles • Clubbing is rare • Rarely BOOP can mimic Bronchogenic CA by presenting as a solitary pulmonary nodule with cavity and hemoptysis • Unilateral BOOP has been described

  15. BOOP- LAB TESTS • High ESR & CRP - secondary to inflammatory process • 1/3rd have a leukocytosis • Chest Xray: Patchy peripheral bilateral migratory alveolar infiltrates • 20-30% - reticular or nodular infiltrate • Pleural effusions in 30% due to secondary BOOP

  16. BOOP- Imaging • CXR- can be normal in 4-10% • Cavitation & lymphadenopathy are absent • Focal consolidation is a marker for a good response to steroid therapy

  17. BOOP- IMAGING • High Resolution CAT scan of Chest: patchy consolidation, ground glass opacity, nodularity with subpleural lower lobe predeliction. • Bronchial wall thickening and dilatation denote severe disease • Honey combing not seen in idiopathic BOOP

  18. PFTs in BOOP • Restrictive Defect with Low Vital capacity • Low DLCo • Resting and exercise induced Hypoxemia • Pressure-Volume curve shifted down and right due to decreased lung compliance • Obstructive defect is not a feature unless patient is a smoker

  19. BOOP- Bronchoscopy • BAL- High lymphocytes and Neutrophils • Foamy macrophages • Low CD4-CD8 ratio • Transbronchial Biopsy may miss representative lesions but may still be useful • Gold standard- Open lung or thoracoscopic lung biopsy for histopathology

  20. BOOP-Pathogenesis • Accelerated host response to injury- • Bacterial or viral antigen; • Inhaled or noxious stimulus  Lung injury Inflammatory cascade  subsequent repair

  21. BOOP-HISTOLOGY • Exuberant inflammation and fibrosis in terminal & respiratory bronchioles. • Terminal bronchioles plugged with granulation tissue, neutrophils, edema, fibrin, connective tissue, myoblasts, fibroblasts. • Extends to peribronchiolar region, alveolar duct and alveolar space - organizing pneumonia component

  22. BOOP-HISTOLOGY • Cells-mononuclear, neutrophils, eosinophils, mutinucleate giant cells. • Lesions in peribronchiolar distribution seen on low power is a clue to diagnosis. • Preserved underlying alveolar architecture • Fibrosis usually does not occur • Stereotypic response to lung injury ie lesions are of same age

  23. BOOP- DIFFERENTIAL DIAGNOSIS • Community Acquired Pneumonia • Drug Reactions, ARDS, • Chronic Eosinophilic Pneumonia, • Lymphoproliferative malignancy, • Bronchogenic ca (bronchoalveolar cell) • Histology may resemble usual intersitial pneumonitis or organising diffuse alveolar damage

  24. BOOP VS OB • Obliterative Bronchiolitis due to RA, toxic fumes, bone marrow or lung transplant • CXR - may be normal • PFTs - obstructive or mixed defect • Pathology - concentric bronchiolar narrowing by intramural fibrosis without interstital involvement

  25. BOOP vs OB • OB- Poor response to steroids • OB- Poor prognosis • OB- No spontaneous recovery

  26. BOOP--Treatment • Spontaneous recovery occurs rarely • Antibiotic therapy for underlying infections • Withdrawal of offending toxin/ drug • Supportive therapy • Steroids for idiopathic BOOP and BOOP secondary to connective tissue disorders

  27. BOOP-STEROID Rx • Prednisone- 0.5-1.0 mg/kg/day x 1-3 mos • Taper slowly over several months on individual basis • Duration of Rx 6- 12 months • Relapse may occur during steroid taper • Monitor by clinical, CXR and PFTs. • Response occurs in days to weeks

  28. BOOP-- STEROID Rx • Idiopathic BOOP responds to steroids better than BOOP due to connective tissue disorders

  29. BOOP-Prognosis • 65%- idiopathic BOOP cases have complete clinical, radiographic and physiologic resolution • 20%-Residual pulmonary fibrosis • 3-10%- mortality rate • Secondary BOOP has poor response to steroid Rx

  30. BOOP- Rx • Immunosuppressive agents - cyclophosphamide, azathioprine for those who fail to respond to steroid Rx • Low dose erythromycin has an immunomodulatory effect

  31. FULMINANT BOOP • Rapidly progressive to respiratory failure requiring mechanical ventilation (9 0f 10 patients in a series by Cohen & Colleagues) • Predisposed by Smoking, drugs, connective tissue disorders and environmental agents • Necropsy-septal inflammation, interstitial fibrosis & honeycombing

  32. FULMINANT BOOP • Rx: High dose steroids and immunosuppressive agents • Course: Death or severe residual pulmonary fibrosis

  33. Summary--BOOP • BOOP represents a nonspecific reaction pattern of lung to a wide variety of insults. • Clinical/Histologic correlation aids in correct assessment of diagnostic, therapeutic and prognostic significance

  34. BOOP- References • Fishman’s Pulmonary Diseases & Disorders: vol 1, 3rd ed, ch. 54 p 825-847 • Comprehensive Respiratory Medicine by R Albert, S Spiro, J Jett, 9 48.4--48.6 • ACCP Pulmonary Board Review 1998-99 p.163-166 J P Lynch III ,MD, FCCP • MKSAP- Pulmonary & Critical Care , 2nd ed,ch.4.S B Fiel, J P Lynch III p 108-116 • BOOP associated with acute Mycoplasma infection Clin Inf Dis 1997 Dec, 25(6):1340-2,Llibre JM, Urban A, Garcia E, Carrasco MA, Murcia C • Low dose erythromycin for treatment of BOOP Kurume Med J, 1993; 40(2);65-7 Ichikawa Y, Ninomiya H, Katsuki M, Hotta M, Tanaka M, Oizumi K • A case of Unilateral BOOP, Nebr Med J,1996 May;81(5):149-51 Kanwar BA,Shehan CJ,Campbell JC, Dewan N, O’Donohue WJ Jr

More Related